Atypical patterns of response to immune checkpoint inhibitors: interpreting pseudoprogression and hyperprogression in decision making for patients' treatment

Concetta Elisa Onesti^{1

2

3}, Pierre Frères², Guy Jerusalem^{2

3}

Affiliations

¹ Laboratory of Human Genetics, GIGA Research Institute, University of Liège, Liège, Belgium.
² Department of Medical Oncology, University Hospital (CHU Liège), Liège, Belgium.
³ Laboratory of Medical Oncology, GIGA Research Institute, University of Liège, Liège, Belgium.

Editorial

Concetta Elisa Onesti et al. J Thorac Dis. 2019 Jan.

. 2019 Jan;11(1):35-38.

doi: 10.21037/jtd.2018.12.47.

Concetta Elisa Onesti^{1

2

3}, Pierre Frères², Guy Jerusalem^{2

3}

¹ Laboratory of Human Genetics, GIGA Research Institute, University of Liège, Liège, Belgium.
² Department of Medical Oncology, University Hospital (CHU Liège), Liège, Belgium.
³ Laboratory of Medical Oncology, GIGA Research Institute, University of Liège, Liège, Belgium.

No abstract available

Conflict of interest statement

Conflicts of Interest: The authors have no conflicts of interest to declare.

Hyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy.
Ferrara R, Mezquita L, Texier M, Lahmar J, Audigier-Valette C, Tessonnier L, Mazieres J, Zalcman G, Brosseau S, Le Moulec S, Leroy L, Duchemann B, Lefebvre C, Veillon R, Westeel V, Koscielny S, Champiat S, Ferté C, Planchard D, Remon J, Boucher ME, Gazzah A, Adam J, Bria E, Tortora G, Soria JC, Besse B, Caramella C. Ferrara R, et al. JAMA Oncol. 2018 Nov 1;4(11):1543-1552. doi: 10.1001/jamaoncol.2018.3676. JAMA Oncol. 2018. PMID: 30193240 Free PMC article.

1. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012;12:252-64. 10.1038/nrc3239 - DOI - PMC - PubMed
1. Abdin SM, Zaher DM, Arafa EA, et al. Tackling Cancer Resistance by Immunotherapy: Updated Clinical Impact and Safety of PD-1/PD-L1 Inhibitors. Cancers (Basel) 2018;10:E32. 10.3390/cancers10020032 - DOI - PMC - PubMed
1. Wolchok JD, Chiarion-Sileni V, Gonzalez R, et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med 2017;377:1345-56. 10.1056/NEJMoa1709684 - DOI - PMC - PubMed
1. Hellmann MD, Ciuleanu TE, Pluzanski A, et al. Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden. N Engl J Med 2018;378:2093-104. 10.1056/NEJMoa1801946 - DOI - PMC - PubMed
1. Motzer RJ, Tannir NM, McDermott DF, et al. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. N Engl J Med 2018;378:1277-90. 10.1056/NEJMoa1712126 - DOI - PMC - PubMed